Xenon Pharmaceuticals Shares Fall Following Clinical Trial Delay
Xenon Pharmaceuticals Shares Fall Following Clinical Trial Delay
Updated at: September 19, 2026 at 03:30 AM
On September 17, 2026, Xenon Pharmaceuticals faced a sharp decline in its share price after announcing a temporary pause in new patient enrollment for its psychiatry clinical trials.
The company is evaluating its drug candidate, azetukalner, for major depressive disorder and bipolar depression.
This decision follows reports of neuropsychiatric adverse events, such as psychosis, which were not seen in earlier research.
Consequently, Xenon’s stock price dropped by nearly 30% as investors expressed concern over the company's psychiatry pipeline.
Crucially, the situation does not affect Xenon's work in epilepsy.
In a positive development, the company submitted a New Drug Application to the FDA for azetukalner as a treatment for focal seizures.
Analysts believe that the safety data for the epilepsy program remains strong, providing a buffer against the negative news in the psychiatry department.
Xenon is now reviewing potential dosing adjustments to improve the drug's tolerability, aiming to address safety issues while maintaining progress in their clinical programs.
